[go: up one dir, main page]

MX2008009929A - Vacuna a base de levadura para inducir una respuesta inmune. - Google Patents

Vacuna a base de levadura para inducir una respuesta inmune.

Info

Publication number
MX2008009929A
MX2008009929A MX2008009929A MX2008009929A MX2008009929A MX 2008009929 A MX2008009929 A MX 2008009929A MX 2008009929 A MX2008009929 A MX 2008009929A MX 2008009929 A MX2008009929 A MX 2008009929A MX 2008009929 A MX2008009929 A MX 2008009929A
Authority
MX
Mexico
Prior art keywords
immune response
eliciting
compositions
useful
yeast
Prior art date
Application number
MX2008009929A
Other languages
English (en)
Inventor
Richard C Duke
Alex Franzusoff
Aurelia Haller
Thomas H King
Yingnian Lu
Victoria Kelley Hodson
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of MX2008009929A publication Critical patent/MX2008009929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a vacunas que pueden ser adaptadas para obtener una respuesta inmune deseada. Esas composiciones que se proveen aquí se usan preferentemente para producir una respuesta inmune humoral mientras que otras composiciones son útiles para producir preferentemente una respuesta mediada por las células. Las combinaciones de las composiciones de vacuna también son útiles para producir ambos tipos de respuesta y/o para modular el tipo de respuesta inmune provocada. La invención también proporciona métodos para provocar una respuesta inmune en un individuo al administrarle las composiciones aquí descritas. Esas respuestas inmunes son útiles para proteger a un individuo de varios tipos de enfermedades, infecciones y condiciones indeseables.
MX2008009929A 2006-02-02 2007-02-02 Vacuna a base de levadura para inducir una respuesta inmune. MX2008009929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Publications (1)

Publication Number Publication Date
MX2008009929A true MX2008009929A (es) 2008-10-01

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009929A MX2008009929A (es) 2006-02-02 2007-02-02 Vacuna a base de levadura para inducir una respuesta inmune.

Country Status (14)

Country Link
US (2) US7736642B2 (es)
EP (2) EP1988919A4 (es)
JP (3) JP5198290B2 (es)
KR (2) KR20140029551A (es)
CN (2) CN101405026B (es)
AU (1) AU2007212076B2 (es)
BR (1) BRPI0706913A2 (es)
CA (1) CA2638815A1 (es)
IL (2) IL193196A (es)
IN (1) IN2014DN08830A (es)
MX (1) MX2008009929A (es)
SG (2) SG169375A1 (es)
TW (2) TW201412329A (es)
WO (1) WO2007092792A2 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
MX2008009929A (es) * 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
EP1998814A4 (en) * 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
CA2657849A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
EP2419126B1 (en) * 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
CA2762044A1 (en) * 2009-05-18 2010-11-25 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva)
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
AU2011312178B2 (en) * 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2627774B1 (en) * 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP2670430B1 (en) * 2011-01-31 2015-04-01 Baxter International Inc Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
AU2012228937B2 (en) * 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
WO2012162342A2 (en) * 2011-05-23 2012-11-29 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
BR112013032381B1 (pt) * 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
RU2017143985A (ru) 2011-08-17 2019-02-14 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
ES2525205T3 (es) 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
US11105802B2 (en) * 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
CN105209063A (zh) * 2013-03-15 2015-12-30 宾夕法尼亚大学理事会 具有抗原和作为佐剂的白细胞介素-23的疫苗
WO2014186047A1 (en) 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
EP4070818A3 (en) * 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
KR102409372B1 (ko) * 2014-04-11 2022-06-16 글로브이뮨 효모 면역 요법 및 타입 i 인터페론 감도
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
CA2995454A1 (en) * 2015-08-11 2017-02-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
WO2017222619A2 (en) 2016-03-24 2017-12-28 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
WO2018200389A1 (en) 2017-04-24 2018-11-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020061203A1 (en) 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CA3138174A1 (en) * 2019-05-21 2020-11-26 David James O'hagan Yeast-based oral vaccination
KR20220152226A (ko) * 2020-02-11 2022-11-15 사이토누스 테라퓨틱스, 인크. 신속한 백신 플랫폼
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
CA3170359A1 (en) 2020-04-14 2021-10-21 Nantcell, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
EP0733113B1 (en) * 1994-01-11 2007-05-02 Vlaams Interuniversitair Instituut voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1294892B1 (en) * 2000-06-23 2007-10-17 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
AU2005248361B2 (en) * 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
CN101052383B (zh) 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
MX2008009929A (es) * 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.

Also Published As

Publication number Publication date
EP2468296A2 (en) 2012-06-27
KR20140029551A (ko) 2014-03-10
IN2014DN08830A (es) 2015-07-10
EP1988919A2 (en) 2008-11-12
TW200806316A (en) 2008-02-01
BRPI0706913A2 (pt) 2011-04-12
JP2009528987A (ja) 2009-08-13
US20100196411A1 (en) 2010-08-05
CN101405026A (zh) 2009-04-08
AU2007212076A1 (en) 2007-08-16
KR20080089671A (ko) 2008-10-07
CA2638815A1 (en) 2007-08-16
TW201412329A (zh) 2014-04-01
JP2013075899A (ja) 2013-04-25
KR101492524B1 (ko) 2015-02-12
US20080003239A1 (en) 2008-01-03
US7736642B2 (en) 2010-06-15
IL193196A0 (en) 2011-08-01
CN101405026B (zh) 2015-04-22
SG10201402236VA (en) 2014-08-28
SG169375A1 (en) 2011-03-30
JP2015038147A (ja) 2015-02-26
EP1988919A4 (en) 2009-06-10
EP2468296A3 (en) 2013-12-04
CN104826102A (zh) 2015-08-12
WO2007092792A2 (en) 2007-08-16
IL193196A (en) 2015-01-29
JP5198290B2 (ja) 2013-05-15
AU2007212076B2 (en) 2012-10-18
IL232518A0 (en) 2014-06-30
WO2007092792A3 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
TW200806316A (en) Yeast-based vaccine for inducing an immune response
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
WO2010019262A3 (en) Polyvalent vaccine
WO2007024941A3 (en) Polyvalent vaccine
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
WO2009156960A9 (en) Novel adjuvant compositions
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
MY159500A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2010060051A3 (en) Systems biology approach predicts the immunogenicity of vaccines
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2009006178A (es) Vacuna contra salmonela.
GB2434367A (en) Improved vaccines
CA2763359C (en) New human rotavirus strains and vaccines
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
HK1211980A1 (en) Multifunctional oral vaccine based on chromosome recombineering
WO2012047267A3 (en) Polyvalent immunogen
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2015048796A3 (en) Mosaic hiv envelope immunogenic polypeptides
WO2011074006A3 (en) Vaccine composition
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration